Denali Therapeutics Inc.

DNLI· NASDAQ· Health Care· Pharmaceuticals, Biotechnology & Life Sciences

$18.94-1.97%

2026-10-30

Financials

Valuation Metrics

Denali Therapeutics Inc.'s Market Cap is $3.01B. At end of 2025 it was $2.90B. Ranked #1705 of 3,116 in US market (top 55%), #610 of 1,472 on NASDAQ (top 41%), #106 of 265 in Pharmaceuticals, Biotechnology & Life Sciences (top 40%) by Market Cap.

Investment Metrics(as of 2026-10-30)

Metric	Value	Rank
Size
Market Cap	$3.01B	US#1,705/3,116 Sec#106/265
Revenue	$4M	US#2,827/3,116 Sec#180/265
Net Income	$-511M	US—/3,116 Sec—/265
Total Assets	$1.16B	US#2,400/3,116 Sec#90/265
Net Assets	$835M	US#1,878/3,116 Sec#77/265
Value
P/B	3.60x	US#1,962/3,116 Sec#114/265
P/S	834.06x	US#2,982/3,116 Sec#196/265
FCF Yield	-14.55%	US—/3,116 Sec—/265
Profitability
ROE	-61.24%	US#2,713/3,116 Sec#175/265
ROA	-44.17%	US#2,958/3,116 Sec#197/265
Op. Margin	-15058.19%	US#2,847/3,116 Sec#186/265
Financial Health
Debt Ratio	38.65%	US#439/3,116 Sec#126/265
Total Debt	$28M	US#2,695/3,116 Sec#178/265
FCF	$-437M	US#2,887/3,116 Sec#248/265
Cash	$202M	US#1,724/3,116 Sec#107/265
Current Ratio	8.37x	US#303/3,116 Sec#92/265
Performance
1Y Return	15.63%	US#1,217/3,116 Sec#113/265
1M Return	-8.37%	US#2,422/3,116 Sec#175/265
From 52W High	-30.62%	US#1,968/3,116 Sec#128/265
1Y MDD	-35.28%	US#1,663/3,116 Sec#92/265
Trading
Volume	1,073,262 shares	US#1,207/3,116 Sec#112/265
Trading Value	$20M	US#1,713/3,116 Sec#130/265
Per Share
EPS	$-3.22	US—/3,116 Sec—/265
BPS	$5.26	US#2,255/3,116 Sec#124/265